WASHINGTON, May 29, 2024 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2024, to be held in Houston, TX from June 1 through June 5, 2024.
The following will be presented:
June 4, 2024
Presentation Title: “Drug Screening and CRISPR/Cas9 Screening of HCN Channels”
Poster Presentation Session: P-17
Poster Number: 10
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Presentation Title: “Melanopsin Crispants in Zebrafish Display Difference in Sleep Latency”
Poster Presentation Session: P-17
Poster Number: 11
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Presentation Title: “Genetic Variants Associated with Dim Light Melatonin Onset in a Delayed Sleep-Wake Phase Disorder Cohort”
Poster Presentation Session: P-22
Poster Number: 146
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Presentation Title: “Genetic variants associated with TST and LPS in insomnia patients: whole genome sequencing study”
Poster Presentation Session: Late-Breaking Abstracts (LBA); P-31
Poster Number: 451
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
For more information on SLEEP 2024, please refer to https://www.sleepmeeting.org/
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
Corporate Contact:Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
[email protected]
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
[email protected]
SOURCE Vanda Pharmaceuticals Inc.
